Pharmaceutical Supply of Sumatriptan Succinate Tablets

The contract solicits the supply of FDA-approved Sumatriptan Succinate Tablets, 100mg, packaged in bottles containing nine tablets each, with full compliance to federal and military labeling requirements. The product must meet all regulatory standards for pharmaceutical distribution within U.S. government channels, particularly those governed by the Department of Defense. The solicitation is issued under the NAICS code 325412, indicating pharmaceutical manufacturing, and is structured as a subcontract within the Medical Supply Chain Pharm FSA framework. All deliveries must be performed to the designated place of performance at JBER, 99506-4400, ensuring alignment with Defense Logistics Agency protocols for military medical supply chains. Responses are due by August 3, 2026, with the solicitation posted on July 26, 2026, and are accessible through the DIBBS platform under reference number SPE2DP26T4284. While no set-aside provisions or specific organization type restrictions are outlined, the requirement is strictly for pre-approved pharmaceuticals meeting federal quality and labeling benchmarks. The absence of a designated point of contact implies that all communications and submissions must follow standard DIBBS procurement procedures. Participation is open to qualified contractors capable of fulfilling the volume and compliance demands of military medical logistics, with an emphasis on timely delivery and adherence to controlled pharmaceutical handling standards.